Structural analogues in herbal medicine ginseng hit a shared target to achieve cumulative bioactivity

By a pilot trial on investigating immunomodulatory activity and target of ginsenosides, the major bioactive components of ginseng, here we report that structural analogues in herbal medicines hit a shared target to achieve cumulative bioactivity. A ginsenoside analogues combination with definite immunomodulatory activity in vivo was designed by integrating pharmacodynamics, serum pharmacochemistry and pharmacokinetics approaches. The cumulative bioactivity of the ginsenoside analogues was validated on LPS/ATP-induced RAW264.7 macrophages. The potentially shared target NLRP3 involved in this immunomodulatory activity was predicted by systems pharmacology. The steady binding affinity between each ginsenoside and NLRP3 was defined by molecular docking and bio-layer interferometry assay. The activation of NLRP3 inflammasomes in LPS/ATP-induced RAW264.7 was significantly suppressed by the combination, but not by any individual, and the overexpression of NLRP3 counteracted the immunomodulatory activity of the combination. All these results demonstrate that the ginsenoside analogues jointly hit NLRP3 to achieve cumulative immunomodulatory activity.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection MassLynxTM (v 4.1) software was used for serum pharmacochemistry and pharmacokinetics data collection; Octet Data Analysis (v7.0) software was used for biolayer interferometry assay data collection.

Data analysis
MassLynxTM (v 4.1) software was used for serum pharmacochemistry data analysis; NIH Image J (v1.52) software was used for western blot and immunofluorescence microscopy data analysis; AutoDock (v4.2.6) software was used for molecular docking data analysis; Octet Data Analysis (v7.0) software was used for biolayer interferometry assay data analysis; Others were analysed by GraphPad Prism (v 8.0.1).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Source data underlying plots shown in main figures are provided in Supplementary Data.

nature research | reporting summary
April 2020 Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative. Ten samples in parallel for in vivo assay and three samples in parallel for in vitro assay.
No data were excluded from the analyses.
In pharmacokinetics assay, intra-and inter-day variations were chosen to determine the precision of the developed HPLC-TQ-MS analysis. For intra-day variability test, the serum sample was extracted and analyzed for six replicates within one day, while for inter-day variability test, the same sample was examined in duplicates for three consecutive days.
Blind experiment was not involved in our study . SIg-, Ia-antigen, Thy-1.2 surface antigen is negative. This cell line does not secrete detectable virus particles, and the XC spot formation test is negative. LPS or PPD treatment for 2 days can induce the decomposition of red blood cells but has no effect on tumor target cells. Passed mycoplasma detection in National Collection of Authenticated Cell Cultures.
All cell lines negative for mycoplasma contamination.

nature research | reporting summary
April 2020 Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals

Wild animals
Field-collected samples

Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.

Dual use research of concern
Policy information about dual use research of concern

Hazards
Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

Experiments of concern
Does the work involve any of these experiments of concern: No Yes The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.

Sample preparation
No misidentified cell lines were found.
Male ICR mice, 6-8 weeks of age Wild animals were not involved in our study.
Each animal was evaluated to be in good health, and then acclimated to the laboratory environment (12 h light/dark cycle, at 23-27 , and 30-60% relative humidity) for one week before experiments. Feed and potable water were provided ad libitum.
Animal facilities and protocols were approved by the Animal Ethics Committee of Jiangsu Province Academy of Traditional Chinese Medicine. All procedures were conducted in strict accordance with Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH Publication No. 80-23;revised in 1978).